Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

3articles mentioning funders

3funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Gilead Sciences ×

Gilead Sciences

This funder is selected. Its supporting articles are shown below.

Gilead Sciences3

Articles mentioning Gilead Sciences

3 articles · page 1 of 1

OC36 Durability of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir-based single tablet regimens in a large cohort of experienced PWH: the BIC-LASTING study

sextrans · abstract · 2026-06-05 · 1 matching annotations

90.5%

Gilead Sciences PWH dolutegravir bictegravir emtricitabine DTG tenofovir alafenamide abacavir HIV-RNA HIV+1 more

…s are limited.Methods BIC-LASTING (GS-IT-380-7317, sponsored by Gilead Sciences) is a retrospective analysis on people with HIV (PWH) enrolled …

OC6 The value of promoting hepatitis and HIV screening in high-prevalence populations: the ‘test in the city’ project

sextrans · abstract · 2026-06-05 · 1 matching annotations

97.4%

Gilead Sciences HIV HCV HBV hepatitis psychoactive substances

…ests for HIV and HCV, and HBsAg for HBV. The project, funded by Gilead Sciences, ran in 2025 and involved third sector organisations, healthcar…

SC34 12 months effectiveness and safety of switching to BIC/FTC/TAF in virologically suppressed people with HIV on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL study)

sextrans · abstract · 2026-06-05 · 1 matching annotations

97.5%

Gilead Sciences tenofovir alafenamide emtricitabine bictegravir PWH ASST Fatebenefratelli Sacco HIV HIV-RNA

…egimens in treatment experienced PWH.This study is sponsored by Gilead Sciences.Abstract SC34 Figure 1–2Abstract SC34 Table 1–2…